Literature DB >> 1471556

The pharmacology and toxicology of disulfiram and its metabolites.

E N Petersen1.   

Abstract

Disulfiram (Antabuse) is one of several aldehyde dehydrogenase (ALDH) inhibitors that raise the plasma level of acetaldehyde following ethanol ingestion. The usually pleasant reaction to ethanol is thereby changed to an unpleasant one, owing to a number of bodily reactions to acetaldehyde. Populations showing genetic polymorphism with a lack of some isozymes of ALDH have exhibited an intolerance to ethanol similar to that seen with disulfiram. A normal isozyme pattern seems to be a prerequisite for the development of alcoholism, which supports the principle of disulfiram treatment. Disulfiram is an irreversible ALDH inhibitor when administered in vivo. Diethylthiomethylcarbamate (Me-DTC) is formed from disulfiram in three metabolic steps. This compound and two further oxidized metabolites appear to be active metabolites of disulfiram. Measurements of plasma Me-DTC or the reduction of leucocyte ALDH 1 activity may be valuable markers for the proper dose titration of disulfiram and the rational use of this drug. Some toxicological points are discussed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1471556     DOI: 10.1111/j.1600-0447.1992.tb03309.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand Suppl        ISSN: 0065-1591


  24 in total

Review 1.  Pharmacotherapies for cocaine dependence.

Authors:  G O'Leary; R D Weiss
Journal:  Curr Psychiatry Rep       Date:  2000-12       Impact factor: 5.285

2.  Genome-wide significant association between alcohol dependence and a variant in the ADH gene cluster.

Authors:  Josef Frank; Sven Cichon; Jens Treutlein; Monika Ridinger; Manuel Mattheisen; Per Hoffmann; Stefan Herms; Norbert Wodarz; Michael Soyka; Peter Zill; Wolfgang Maier; Rainald Mössner; Wolfgang Gaebel; Norbert Dahmen; Norbert Scherbaum; Christine Schmäl; Michael Steffens; Susanne Lucae; Marcus Ising; Bertram Müller-Myhsok; Markus M Nöthen; Karl Mann; Falk Kiefer; Marcella Rietschel
Journal:  Addict Biol       Date:  2011-10-18       Impact factor: 4.280

3.  Redirecting apoptosis to aponecrosis induces selective cytotoxicity to pancreatic cancer cells through increased ROS, decline in ATP levels, and VDAC.

Authors:  Richard D Dinnen; Yuehua Mao; Wanglong Qiu; Nicholas Cassai; Vesna N Slavkovich; Gwen Nichols; Gloria H Su; Paul Brandt-Rauf; Robert L Fine
Journal:  Mol Cancer Ther       Date:  2013-10-14       Impact factor: 6.261

4.  A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy.

Authors:  Adam M Spivak; Adriana Andrade; Evelyn Eisele; Rebecca Hoh; Peter Bacchetti; Namandjé N Bumpus; Fatemeh Emad; Robert Buckheit; Elinore F McCance-Katz; Jun Lai; Margene Kennedy; Geetanjali Chander; Robert F Siliciano; Janet D Siliciano; Steven G Deeks
Journal:  Clin Infect Dis       Date:  2013-12-12       Impact factor: 9.079

5.  Formation of active products of benzaldehyde dimethane sulfonate (NSC 281612, DMS612) in human blood and plasma and their activity against renal cell carcinoma lines.

Authors:  Robert A Parise; Bean N Anyang; Julie L Eiseman; Merrill J Egorin; Joseph M Covey; Jan H Beumer
Journal:  Cancer Chemother Pharmacol       Date:  2012-10-05       Impact factor: 3.333

6.  Aldehyde dehydrogenase 1B1: molecular cloning and characterization of a novel mitochondrial acetaldehyde-metabolizing enzyme.

Authors:  Dimitrios Stagos; Ying Chen; Chad Brocker; Elizabeth Donald; Brian C Jackson; David J Orlicky; David C Thompson; Vasilis Vasiliou
Journal:  Drug Metab Dispos       Date:  2010-07-08       Impact factor: 3.922

7.  The ethanol metabolite acetaldehyde inhibits the induction of long-term potentiation in the rat dentate gyrus in vivo.

Authors:  K Abe; S Yamaguchi; M Sugiura; H Saito
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

8.  Characterization of the metabolism of benzaldehyde dimethane sulfonate (NSC 281612, DMS612).

Authors:  Robert A Parise; Julie L Eiseman; Dana M Clausen; Kimberly P Kicielinski; Pamela A Hershberger; Merrill J Egorin; Jan H Beumer
Journal:  Cancer Chemother Pharmacol       Date:  2015-07-21       Impact factor: 3.333

9.  Pharmacoprophylaxis of alcohol dependence: Review and update Part I: Pharmacology.

Authors:  Sandeep Grover; Gaurav Bhateja; Debasish Basu
Journal:  Indian J Psychiatry       Date:  2007-01       Impact factor: 1.759

10.  Pharmacotherapies and personalized medicine for alcohol use disorder: a review.

Authors:  Falk W Lohoff
Journal:  Pharmacogenomics       Date:  2020-08-18       Impact factor: 2.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.